Antineoplastic Combined Chemotherapy Protocols
"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
MeSH Number(s)
E02.183.750.500
E02.319.077.500
E02.319.310.037
Concept/Terms
Antineoplastic Combined Chemotherapy Protocols- Antineoplastic Combined Chemotherapy Protocols
- Antineoplastic Agents, Combined
- Agent, Combined Antineoplastic
- Agents, Combined Antineoplastic
- Antineoplastic Agent, Combined
- Combined Antineoplastic Agent
- Drug Combinations, Antineoplastic
- Antineoplastic Drug Combinations
- Antineoplastic Drug Combination
- Combinations, Antineoplastic Drug
- Drug Combination, Antineoplastic
- Combined Antineoplastic Agents
- Anticancer Drug Combinations
- Anticancer Drug Combination
- Drug Combination, Anticancer
- Drug Combinations, Anticancer
- Antineoplastic Combined Chemotherapy Regimens
Antineoplastic Chemotherapy Protocols- Antineoplastic Chemotherapy Protocols
- Antineoplastic Chemotherapy Protocol
- Chemotherapy Protocol, Antineoplastic
- Protocol, Antineoplastic Chemotherapy
- Protocols, Antineoplastic Chemotherapy
- Chemotherapy Protocols, Antineoplastic
- Cancer Chemotherapy Protocols
- Cancer Chemotherapy Protocol
- Chemotherapy Protocol, Cancer
- Chemotherapy Protocols, Cancer
- Protocol, Cancer Chemotherapy
- Protocols, Cancer Chemotherapy
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".
This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Harvard Catalyst Profiles by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 42 | 17 | 59 |
1995 | 39 | 17 | 56 |
1996 | 55 | 23 | 78 |
1997 | 56 | 17 | 73 |
1998 | 70 | 23 | 93 |
1999 | 58 | 32 | 90 |
2000 | 61 | 27 | 88 |
2001 | 59 | 22 | 81 |
2002 | 69 | 31 | 100 |
2003 | 75 | 40 | 115 |
2004 | 85 | 39 | 124 |
2005 | 103 | 40 | 143 |
2006 | 109 | 54 | 163 |
2007 | 97 | 49 | 146 |
2008 | 112 | 60 | 172 |
2009 | 135 | 55 | 190 |
2010 | 148 | 52 | 200 |
2011 | 145 | 72 | 217 |
2012 | 162 | 59 | 221 |
2013 | 163 | 70 | 233 |
2014 | 198 | 101 | 299 |
2015 | 203 | 83 | 286 |
2016 | 175 | 93 | 268 |
2017 | 183 | 104 | 287 |
2018 | 233 | 78 | 311 |
2019 | 271 | 92 | 363 |
2020 | 225 | 133 | 358 |
2021 | 187 | 160 | 347 |
2022 | 45 | 232 | 277 |
2023 | 9 | 222 | 231 |
2024 | 1 | 43 | 44 |
Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
CRE24-044: Response to Dabrafenib and Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Metastatic Non-Small Cell Lung Cancer. J Natl Compr Canc Netw. 2024 Apr 05; 22(2.5).
-
A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma. Oncologist. 2024 Apr 04; 29(4):324-331.
-
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J. Clin Cancer Res. 2024 Apr 01; 30(7):1273-1280.
-
Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024 Apr 13; 403(10435):1460-1471.
-
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nat Commun. 2024 Mar 27; 15(1):2691.
-
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide. Blood Cancer J. 2024 Mar 26; 14(1):55.
-
Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med. 2024 Mar 21; 390(12):1080-1091.
-
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. Nat Commun. 2024 Mar 19; 15(1):2446.
-
Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer. Oncotarget. 2024 Mar 19; 15:238-247.
-
Comparative Efficacy and Safety of Standard and Biweekly Trifluridine/Tipiracil Regimen in Patients With Colorectal Cancer. Anticancer Res. 2024 Mar; 44(3):1219-1226.